RESUMO
Ninety-two outpatients (31 women, 61 men) who were treated with oral sildenafil for psychotropic-induced sexual dysfunction (PISD) completed ratings of their sexual functioning pre- and posttreatment. Both women and men reported significant improvements (p = .001) in all domains of sexual functioning, with 88% reporting improvement in overall sexual satisfaction. Significant improvements were reported regardless of psychotropic medication type. However, patients taking selective serotonin re-uptake inhibitors reported less improvement in arousal, libido, and overall sexual satisfaction than did other patients, whereas patients taking benzodiazepines reported significantly more improvement in libido and overall sexual satisfaction. Oral sildenafil may be an effective treatment for PISD.
Assuntos
Inibidores de Fosfodiesterase/uso terapêutico , Piperazinas/uso terapêutico , Psicotrópicos/efeitos adversos , Disfunções Sexuais Psicogênicas/induzido quimicamente , Adulto , Nível de Alerta/efeitos dos fármacos , Feminino , Humanos , Libido/efeitos dos fármacos , Masculino , Satisfação Pessoal , Inibidores de Fosfodiesterase/farmacologia , Piperazinas/farmacologia , Purinas , Estudos Retrospectivos , Fatores Sexuais , Citrato de Sildenafila , SulfonasRESUMO
Seven of 21 refractory depressed patients responded within 7 days to combined thyroid hormone-antidepressant treatment. Five of the 7 responders revealed evidence of subclinical hypothyroidism, suggesting that this subpopulation of depressed patients may benefit most from adjunctive thyroid hormone.
